These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7757855)

  • 21. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 22. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 23. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 24. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 25. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 26. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
    Roberts R; Rodriguez W; Murphy D; Crescenzi T
    JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 30. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 31. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 32. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA labeling status of pediatric medications.
    Yoon EY; Davis MM; El-Essawi H; Cabana MD
    Clin Pediatr (Phila); 2006; 45(1):75-7. PubMed ID: 16429220
    [No Abstract]   [Full Text] [Related]  

  • 34. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 35. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 36. Paediatric labelling requirements. Implications for pharmacokinetic studies.
    Wilson JT; Kearns GL; Murphy D; Yaffe SJ
    Clin Pharmacokinet; 1994 Apr; 26(4):308-25. PubMed ID: 8013163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 39. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 40. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.